類別
特色產品
tirzepatide 10mg
tirzepatide 10mg: Balanced-Dose Research Peptide for Metabolic Pathway Exploration
Tirzepatide 10mg emerges as a versatile research tool, offering a balanced concentration of dual GLP-1 and GIP receptor agonism to study metabolic pathways with precision. 該研究級肽, formulated at 10mg, is ideal for investigating therapeutic-range effects, dose-response relationships, and multi-hormonal interactions—making it a cornerstone for preclinical studies aiming to bridge basic science and potential clinical applications.
The Advantage of Tirzepatide 10mg in Research
Distinguished from higher or lower doses, Tirzepatide 10mg provides a mid-range potency that mirrors physiological relevance. Its dual-receptor activation stimulates insulin secretion, inhibits glucagon release, and regulates satiety signals through harmonized GLP-1 and GIP pathways. This balance allows researchers to explore moderate metabolic responses, identify optimal therapeutic windows, and compare outcomes across different dosing paradigms in preclinical models.
初步研究應用
Therapeutic Efficacy Studies
Perfect for evaluating standard-dose effects in type 2 diabetes and obesity research, Tirzepatide 10mg facilitates investigations into glycemic stability, gradual weight management, and sustained insulin sensitivity. It supports studies on long-term metabolic regulation, helping researchers assess the durability of dual-agonist effects in chronic conditions.
Mechanistic Pathway Analysis
This formulation enables detailed exploration of how GLP-1 and GIP pathways interact at a moderate dose. Researchers can study adipose tissue metabolism, hepatic glucose regulation, and gastrointestinal hormone crosstalk—key areas for understanding the underlying mechanisms of metabolic disorders and potential therapeutic interventions.
產品詳情
Each vial contains 10mg of lyophilized Tirzepatide with ≥99% purity, ensuring reliable and reproducible research results. 需要用抑菌水重建 (available separately). 僅用於研究—not intended for human or animal consumption.
Tirzepatide 10mg empowers scientists to delve into the nuances of dual-agonist therapy, offering critical insights into metabolic regulation that can inform the development of targeted treatments for metabolic diseases through rigorous preclinical research.
留言